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Abstract
Purpose of Review To provide an overview of the role of genes and loci that predispose to Paget’s disease of bone and related
disorders.
Recent Findings Studies over the past ten years have seen major advances in knowledge on the role of genetic factors in Paget’s
disease of bone (PDB). Genome wide association studies have identified six loci that predispose to the disease whereas family
based studies have identified a further eight genes that cause PDB. This brings the total number of genes and loci implicated in
PDB to fourteen. Emerging evidence has shown that a number of these genes also predispose to multisystem proteinopathy
syndromes where PDB is accompanied by neurodegeneration and myopathy due to the accumulation of abnormal protein
aggregates, emphasising the importance of defects in autophagy in the pathogenesis of PDB.
Summary Genetic factors play a key role in the pathogenesis of PDB and the studies in this area have identified several genes
previously not suspected to play a role in bone metabolism. Genetic testing coupled to targeted therapeutic intervention is being
explored as a way of halting disease progression and improving outcome before irreversible skeletal damage has occurred.
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Introduction
Paget’s disease of bone (PDB) is a common skeletal disorder,
characterised by focal regions of abnormal and disorganised
bone remodelling at one (monostotic) or more (polyostotic)
sites. The disease mainly involves the axial skeleton, such that
the pelvis (70%), femur (55%), lumbar spine (53%), skull
(42%), and tibia (32%) are preferentially affected. Clinically,
the disease result in symptoms of bone pain, deformity, and
pathological fracture. Osteoarthritis related to bone deformity
and subchondral sclerosis is a common consequence and fre-
quently requires arthroplasty [1]. Patients with PDB also have
an increased risk of developing osteosarcoma, and although
rare (0.3% of PDB patients), virtually all osteosarcomas that
occur in adulthood do so in patients with PDB [2]. Similarly,
some families have been described in which PDB is accompa-
nied by giant cell tumours [3].
Epidemiology
Paget’s disease of bone (PDB) is estimated to affect about
2% of the UK population over 55 years of age, with a
greater incidence in men (1.4:1) [2]. There is marked geo-
graphical variation in the occurrence of PDB. The UK has
the highest incidence of PDB in the world, but the disease
is also common in other European countries such as
Spain, Italy, and France. It is also common in people of
European descent, and because of this, the incidence is
high in countries that have historically been common des-
tinations for migration of these communities, such as
Australia, Canada, New Zealand, South Africa, and the
USA [4, 5]. In contrast, PDB is rare in the Indian subcon-
tinent, Scandinavia, China, and the Far East [6].
The incidence of PDB increases markedly with age; it is
rare below the age of 50 years, but doubles each decade
thereafter affect about 7.6% of men and 5.4% of women
by the eighth decade in the UK [7]. The striking geographic
variation in PDB and correlation with trends in the migra-
tion of certain population cohorts has emphasised the im-
portance of genetic factors in the pathogenesis of PDB.
Environmental factors also play a significant role however,
reflected by the reduced incidence and severity of PDB in
several locations including the UK, continental Europe, and
This article is part of the Topical Collection on Genetics
* Stuart H. Ralston
stuart.ralston@ed.ac.uk
1 Centre for Genomic and Experimental Medicine, Institute of




New Zealand [2, 8, 9], but no significant change in other
regions such as Italy and the USA [10–12]. The identity of
environmental triggers for PDB is unclear [13]. Full discus-
sion of this area is beyond the scope of this article, but
suggested environmental influences include low dietary
calcium intake [14], vitamin D deficiency [15], excessive
biomechanical loading [16], tobacco use [17], wood heating
during childhood [18], lead exposure [19, 20], air pollution
[21], contact with animals [22], and a slow virus infection
with one of the paramyxoviruses [23, 24].
Inheritance of Paget’s Disease
Familial clustering is common in classical PDB, and in
some families the disease is inherited in an autosomal dom-
inant manner. In the UK, a family history of PDB is obtain-
ed in around 15% of PDB cases but in other regions such as
Quebec, a positive family history is obtained in up to 50% of
individuals [25]. It has been estimated that penetrance
reaches 80–90% by the seventh decade in people who carry
mutations in SQSTM1 which is the most important predis-
posing gene for PDB [26–28] (see below). The relative risk
of developing PDB in relatives of an affected individual is
approximately seven times greater than in relatives of con-
trols, and this rises to 20 times for relatives of patients with
severe or early-onset disease [29]. Traditionally PDB is
characterised into familial or sporadic subtypes, based on
the presence of a positive family history, but it is important
to remember that as the disease may be asymptomatic, fam-
ily history may be more common than one thinks.
A number of rare syndromes have been identified in which
clinical, radiological, or histological features in common with
PDB are observed but where there is an early age at onset and
the diseases are inherited in a Mendelian manner. The clinical
and pathophysiological features of these disorders have re-
cently been reviewed elsewhere [30•], but the genes responsi-
ble will also be discussed here.
A significant observation from recent findings has been the
relatively large effect sizes of the loci influencing the devel-
opment of PDB compared with other common diseases of the
musculoskeletal system, such as osteoporosis and rheumatoid
arthritis [31••]. This indicates that susceptibility to PDB is
likely to be mediated by the inheritance of a relatively small
number of genes with large effect sizes as opposed to a large
number of genes with small effect sizes. For example, a num-
ber of common variants have been identified within or close to
genes such as CSF1, TNFRSF11A, TM7SF4, NUP205, and
RIN3which individually are not sufficient to cause the disease
but which act cumulatively to significantly increase the risk of
developing PDB.
Candidate Genes for Paget’s Disease
Several genes and loci that predispose to familial PDB have
been identified over the last two decades by a combination of
linkage analysis in families and genome wide association
studies (GWAS) in unrelated individuals. Many of the PDB-
associated genes have important roles in osteoclast differenti-
ation and function as illustrated in Fig. 1.
Colony Stimulating Factor 1
Variants at the colony stimulating factor 1 (CSF1) locus on
chromosome 1p13 were identified as predisposing to PDB by
a GWAS study in 2010 [31••] and replicated in a further
GWAS study [32••] more recently. The CSF1 gene encodes
macrophage-colony stimulating factor (M-CSF). This protein
has a critical role in osteoclast formation and survival and is a
strong functional candidate for PDB susceptibility [33]. The
M-CSF protein binds to its receptor (c-FMS), resulting in a
signalling cascade which leads to the activation of ERK (ex-
tracellular signal-regulated kinase) and AKT (protein kinase
B), activating genes that promote the proliferation and surviv-
al of osteoclast precursors. Clinical studies have shown that
patients with PDB have increased serum levels of M-CSF,
supporting the role of CSF1 in the pathogenesis of PDB
[34]. The single nucleotide polymorphisms (SNPs) associated
with PDB are located upstream of the gene in a region rich in
regulatory elements, suggesting that the association may be
due to an effect on regulation ofCSF1 expression but the exact
mechanisms by which these variants predispose to PDB re-
main to be established.
Heterogeneous Nuclear Ribonucleoproteins
Mutations in the heterogeneous nuclear ribonucleoprotein A2/
B1 (hnRNPA2B1) and hnRNPA1 genes were identified as a
cause of multisystem proteinopathy in which PDBwas a com-
ponent part by a genome sequencing approach in families
[35••]. The disease-causing mutations increase the propensity
of the proteins to assemble into fibrils and to be recruited into
cytoplasmic ‘stress granules’ (reviewed by Ralston and Taylor
[30•]). It is of interest that a family has been described in
which a pP310Lmutation in hnRNPA2B1 occurred in patients
with PDB who did not experience myopathy or neurodegen-
eration [36•].
Nucleoporin 205
The nucleoporin 205 (NUP205) gene on chromosome 7q33
was identified as possible candidate for PDB by an extended
GWAS in 2011 [32••]. The strongest signal was with the
rs4294134 within intron 22 of the gene. The NUP205 protein
is involved in the nuclear pore complex (NPC) which is
Curr Osteoporos Rep
responsible for transport of molecules from the cytoplasm to
the nucleus. The role of NUP205 in bone is currently unclear,
but a previous study demonstrated that inactivating missense
mutations in NUP205 are associated with steroid-resistant ne-
phrotic syndrome [37, 38]. Another gene within the 7q33
locus that may be a stronger candidate is STMP1which is also
located within the 7q33 locus. Mullin and colleagues recently
reported that rs4294134 was an expression quantitative trait
locus for STMP1which was found to be expressed in a human
osteoclast specific cDNA library [39•]. The STMP1 gene
Fig. 1 Genes implicated in Paget’s disease and related syndromes. Panel
a shows some genes implicated in the pathogenesis of PDB which have
effects on osteoclast differentiation and bone resorption. The gene
products implicated in PDB are highlighted in red text. Panel b shows
genes thought to affect intracellular signalling in osteoclasts and
osteoclast precursors. The implicated gene products are highlighted in
red and mostly affect the NFκB signalling pathway by interacting with
SQSTM1 or genes that regulate signalling downstream of the RANK
receptor. The ZNF678 gene encodes a transcription factor, but the exact
mechanisms by which it predisposes to PDB are unclear. Abbreviations:
c-fms - Colony Stimulating Factor 1 Receptor; M-CSF - Macrophage
Colony Stimulating factor; RANK - Receptor Activator of Nuclear
Factor Kappa B; RANKL - RANK Ligand; DC-STAMP - Dendritic
Cell Specific Transmembrane Protein; OPG - Osteoprotegerin; RIN3 -
Ras and Rab Interactor 3; IFN - Interferon; IFNR - Interferon Receptor;
STAT - Signal Transducers and Activators of Transcription; TRAF 6 -
Tumour Necrosis Factor Receptor Associated Factor 6; CYLD -
Cylindromatosis; p62 - Sequestosome 1; aPKC - atypical Protein
Kinase C; IKK - Inhibitor of Kappa B Kinase; IkB - Inhibitor of Kappa
B; NFκB - Nuclear Factor Kappa B; OPTN - Optineurin, PFN1 - Profilin
1; NUP205 - Nucleoporin 205; ZNF687 - Zinc Finger Protein 687; Short
Transmembrane Mitochondrial Protein 1.
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encodes a short transmembrane mitochondrial protein whose
function in bone is unclear.
Optineurin
The optineurin gene (OPTN) on chromosome 10p13 was
identified as a candidate for PDB by linkage studies in fami-
lies [40] and GWAS studies [31••, 32••]. The strongest asso-
ciation in GWAS was observed with the rs1561570 variant
within the OPTN gene which increased the risk of PDB by
about 1.6-fold. TheOPTN gene encodes optineurin, which is a
widely expressed cytoplasmic protein with multiple cellular
functions, including in NFκB signalling [41], autophagy, and
innate immunity [42]. Previous studies have identified a neg-
ative regulatory role for OPTN in osteoclast differentiation by
modulating NFκB and interferon signalling both in vitro and
in vivo in mouse models [43]. It has been shown that OPTN
appears to negatively regulate RANKL-induced NFκB acti-
vation in osteoclast precursors by a mechanism requiring
ubiquitin binding and involves an interaction with CYLD
[43]. Knockdown of optineurin in bone marrow-derived mac-
rophages was found to enhanced osteoclast differentiation and
hypernucleation [43]. Furthermore, mice with a loss of func-
tion mutation in Optn exhibited enhance bone turnover and
increased sensitivity of osteoclast precursors to RANKL stim-
ulation [43]. The predisposing variant in humans is associated
with significantly reduced OPTN mRNA expression. This in-
dicates that OPTN is a negative regulator of osteoclast differ-
entiation and function and that the predisposing variant in
humans reduces OPTN expression, thereby increasing osteo-
clast activity.
Promyelocytic Leukaemia Gene
The promyelocytic leukaemia gene (PML) on 15q24.1 was
identified as a candidate for PDB following a GWAS study
in 2011 [32••]. Although the locus contains two genes, PML
was the most obvious candidate. The PML gene gained its
name as it was discovered as a tumour suppressor that is
disrupted in acute promyelocytic leukaemia resulting in its
fusion to the gene retinoic acid receptor alpha (RARA) [44].
It has also been shown to be involved inmultiple other cellular
pathways, such as in regulation of cell growth, senescence,
apoptosis, DNA repair, stem cell maintenance, protein degra-
dation, autophagy, and antiviral responses [45]. Furthermore,
it appears to maintain genome integrity and stability through
recognition of DNA damage and organisation of multiple
DNA repair complexes [46, 47].
Until recently the role of PML in bone metabolism was
unknown, but previous studies suggested that it may regulate
myeloid cell differentiation, proliferation, and osteogenic dif-
ferentiation of mesenchymal stem cells [48, 49]. Recent pre-
liminary studies published in abstract form have shown that
PDB patients have reduced levels of PML expression com-
pared with controls, and in vitro and in vivo studies have
revealed that decreased expression of PML leads to increased
osteoclast differentiation and activity [50]. Although the
mechanisms by which PML variants predispose to PDB in
humans are incompletely understood, it seems likely that they
do so by increasing osteoclast differentiation and function.
Profilin 1
A frameshift mutation in the profilin 1 gene (PFN1)was iden-
tified as a cause of severe early-onset PDB by a genome se-
quencing approach in a large family from Campania in Italy
[51••]. Interestingly, three members of the family also devel-
oped osteosarcoma at a relatively young age. The causal mu-
tation was predicted to produce a truncated variant of the gene
product profilin-1. Functional studies showed that the abnor-
mal protein increased osteoclast formation andmultinuclearity
in vitro in RAW273 cells and that the truncated protein also
formed abnormal aggregates when expressed in a neuroblas-
toma cell line [51••]. Further studies also demonstrated evi-
dence for loss-of-heterozygosity for the PFN1 gene in about
2% of patients with sporadic PDB from the same region of
Italy. It is of interest that previously, mutations of PFN1 had
been identified by other investigators as a cause of amyotro-
phic lateral sclerosis (ALS) and that when the abnormal pro-
teins were studied in vitro, insoluble protein aggregates were
formed [52]. From these observations, it would appear that
PFN1-mediated PDB may represent an example of multisys-
tem proteinopathy, recently coined as the subtype ‘multisys-
tem proteinopathy 7 (MSP7)’ [53].
Ras and Rab Interactor 3
The Ras and Rab interactor (RIN3) gene on chromosome
14q33 was identified as a candidate for PDB by extended
GWAS. The strongest signal was tagged by the SNP
rs10498635 within the gene encoding RIN3. The RIN3 gene
encodes Rab and Ras interactor protein 3, which acts as a
guanine nucleotide exchange factor (GEF) for the Rab5 fam-
ily of proteins including Rab5 itself and RAb31 [54].
Members of the RIN family interact with various proteins
through functional domains they share, playing a role in en-
docytosis, vesicular trafficking, and signal transduction. These
proteins are known to have a role in regulating osteoclast
function through their effects on vesicular trafficking, but until
recently, the role of RIN3 in bone metabolism had not been
specifically studied [55]. Functional studies have shown that
RIN3 mRNA is expressed in bone tissue and its expression
level is approximately 10-fold higher in osteoclasts compared
with osteoblasts [56]. The same authors also detected Rin3
protein in human osteoclasts from bone sections of a patient
with giant cell tumour of bone, [56]. Functional studies have
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shown that Rin3−/− mice have increased bone mass and re-
duced osteoclastic bone resorption in vivo but that osteoclast
differentiation and survival in vitro are normal [57]. From this
it was concluded that likely variants in RIN3 predispose to
PDB through a gain-in-function. Interestingly Pavlos et al.
[58] found a similar phenotype in mice with inactivation of
the small GTPase Rab3D (a potential target for RIN3), raising
the possibility that RIN3 may act as a GEF not only for the
Rab5 sub-family of GTPases as has previously been reported
[58–59] but also for Rab3D [59]. Having said that, further
investigation is required to evaluate the specific pathway by
which variants in RIN3 produce their observed phenotypic
effects.
Transcription Factor SP7
The transcription factor SP7 gene (SP7) was identified by
Whyte and colleagues as a potential cause of early-onset
PDB in a patient with an osteosclerotic disorder characterised
by high bonemass, bone deformity, and pathological fractures
during childhood. The patient had a raised serum ALP,
hypertelorism, and a broad forehead with prominence of the
frontal bone. There were bowing deformities of both femora.
The clinical features were felt to be consistent with juvenile
PDB [60•]. Genetic analysis revealed a heterozygousmutation
at codon 309 (pS309T) causing a substitution of tryptophan
for serine in a conserved region of the SP7 gene product,
Osterix. Histological analysis showed evidence of woven
bone, but this did not show the characteristic features of in-
creased osteoclastic bone resorption that is usual in PDB. The
SP7 gene encodes Osterix, a transcription factor essential for
osteoblast differentiation. Loss of function mutations in SP7
are a recognised cause of osteogenesis imperfecta, and this is
thought to occur as the result of reduced bone formation. It
therefore seems likely that the pS309T mutation causes gain
of function of Osterix and works by increasing bone forma-
tion, leading to production of woven bone and associated bone
deformity and increased bone fragility.
Sequestosome 1
Mutations in the sequestosome 1 (SQSTM1) gene were iden-
tified by genome wide linkage studies as a cause of familial
PDB in two independent populations [27, 28]. Researchers in
Quebec identified a proline to leucine mutation at codon 392
of the protein (P392L) as a cause of the disease [61], and soon
after, this and other mutations were identified in the ubiquitin-
associated (UBA) domain as the cause of the disease in people
of UK descent [62]. A large number of SQSTM1 mutations
have now been reported in PDB patients across the world,
most of which affect the UBA domain [61–65]. The frequency
with which SQTSM1mutations occur in PDB varies in differ-
ent countries, but in the UK, it has been estimated that they
occur in about 40% of familial PDB cases and up to 10% of
sporadic cases [25, 66]. The SQSTM1 gene encodes p62, an
adaptor protein in the NFκB signalling pathway [67]. This
protein has a role in regulation of signalling downstream of
the RANK, tumour necrosis factor (TNF), and neurotrophic
growth factor (NGF) receptors [68] but also appears to play a
key role in regulating other cellular processes through its in-
volvement in autophagy [69–71]. This has recently been
shown to be dysregulated in preclinical models of SQSTM1-
mediated PDB [72] and by the finding of associations between
SNP of genes in the autophagy pathway and PDB [73].
The mechanisms by which mutations in SQSTM1 lead to
PDB are not yet fully understood, but a common feature is
their interference in the ability of p62 to bind ubiquitin [74].
This leads to enhanced NFκB signalling and increased sensi-
tivity of osteoclast precursors to RANK-ligand (RANKL).
Transmembrane 7 Superfamily Member 4
The transmembrane 7 superfamily member 4 (TM7SF4) gene
on chromosome 8q22 encodes a seven-pass transmembrane
protein that is primarily expressed in dendritic cells. It was
identified as being associated with PDB by an extended
GWAS in 2011 [32••]. The strongest association was within
an 18-kb linkage disequilibrium block spanning the TM7SF4
gene. There is a strong functional rationale for this being a
candidate gene for PDB since it encodes a dendritic cell-
specific transmembrane protein (DC-STAMP) which is up-
regulated by RANKL in osteoclast precursors [75] where it
is required for fusion of osteoclast precursors to form mature
osteoclasts [76]. A potential ligand for DC-STAMP is con-
nective tissue growth factor (CCN2) which results in stimula-
tion of osteoclastogenesis [77].
The variant identified by GWAS is also an expression
quantitative trait locus for expression of TM7SF4 in peripheral
blood monocytes and osteoclasts raising the possibility that
variants at this locus predispose to PDB by upregulating
TM7SF4 expression, thereby enhancing osteoclast fusion
[39•, 78]. Some rare variants have also been identified in the
protein coding region of TM7SF4 in patients with PDB, but it
is unclear what effects they have on protein function.
Tumour Necrosis Factor Receptor Superfamily
Member 11A
The tumour necrosis factor receptor superfamily member 11A
(TNFSRF11A) gene on chromosome 18q21 encodes receptor
activator of nuclear factor kappa B (RANK) which is a sig-
nalling molecule that plays an essential role in osteoclast dif-
ferentiation and function. The TNFRSF11A gene was first
implicated in the pathogenesis of PDB through linkage studies
followed by positional cloning in familial expansile osteolysis
(FEO) and early-onset familial Paget’s disease which
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identified mutations affecting the first exon of RANK as the
cause of both disorders [79]. Subsequently similar mutations
were identified as the cause of expansile skeletal
hyperphosphatasia and panostotic expansile bone disease
[30•]. The responsible mutations are duplications of between
15 and 27 nucleotides in the first exon of TNFRSF11A which
add between five and nine additional amino acid residues into
the RANK signal peptide, preventing its cleavage [79]. The
abnormal RANK molecules accumulate in the Golgi appara-
tus [80] and promote osteoclast differentiation, probably by
activating the unfolded protein response. Linkage studies in
classical PDB also showed linkage to the same region of
18q21 with genetic heterogeneity [81] leading to investiga-
tions of the role of TNFRSF11A in classical PDB [82]. An
association was observed with rs1805034 which codes for
an alanine to valine amino acid change at codon 192
(pA192V). A significant association between pA192V and
PDB was also reported in a case control study in an Italian
population [83]. The mechanism by which the pA192V poly-
morphism predisposes to PDB is unclear since in silico anal-
ysis has predicted it to be a conservative change and functional
studies have not showed differences in the ability of the two
variants to stimulate NFκB activation in vitro [82]. The can-
didacy of TNFRSF11A as a predisposing gene for classical
PDB was confirmed by a genome wide association study
which showed association between PDB and the rs2957128
and rs3018362 variants in the 3′ flank of the TNFRSF11A
gene [31••]. These variants are in moderate linkage disequi-
librium with the pV192A variant, but at the present time, the
molecular mechanisms by which TNFRSF11A variants pre-
dispose to PDB are incompletely understood.
Tumour Necrosis Family Receptor Superfamily
Member 11B
Loss of function mutations in the tumour necrosis family re-
ceptor superfamily member 11B gene (TNFRSF11B) were
identified as a cause of the syndrome of juvenile PDB. This
is a rare recessive disorder associated with grossly abnormal
bone remodelling, bone expansion, and bone deformity pre-
senting in childhood and adolescence. It is caused by various
loss of function mutations affecting TNFRSF11B [84] which
encodes osteoprotegerin (OPG), an inhibitor of osteoclast dif-
ferentiation and function [84, 85]. Mutations of TNFRSF11B
have not yet been detected in classical PDB, but there is some
evidence from association studies to suggest that common
variants at the TNFRSF11B locus may predispose to PDB in
women but not men [86, 87].
Valosin-Containing Protein
Mutations in the valosin-containing protein (VCP) gene were
identified as the cause of the syndrome of hereditary inclusion
body myopathy, PDB, and frontotemporal dementia
(IBMPFD) [88]. The VCP gene encodes p97 which is a mul-
tifunctional protein involved in several intracellular processes
including NFκB signalling, DNA repair, and autophagy. The
mechanisms of neurological dysfunction and myopathy are
incompletely understood but are likely to involve a general
defect in ubiquitin mediated protein degradation with accumu-
lation of abnormal protein aggregates which cause cellular
toxicity. The PDB component is less well understood but
may be due at least in part to increased sequestration of IκB
with activation of NFκB. Since its original description, the
IBMPFD syndrome associated with VCP mutations has been
reclassified as one of the multisystem proteinopathies, which
are multisystem disorders in which neurological and muscle
dysfunction are sometimes accompanied by PDB [89].
Zinc Finger Protein 687
Mutations in the zinc finger protein 687 (ZNF687) gene were
identified as a cause of severe early-onset PDB by a genome
sequencing approach in a large family with autosomal domi-
nant inheritance of PDB from the Campania region of Italy
[90••]. The PDB was accompanied by giant cell tumour
(CGT) in 4/14 (28.5%) of affected patients from this family.
The causal mutation in the index family was a proline to argi-
nine amino acid substitution at codon 937 (pP937R) of
ZNF687. Subsequently sequencing of other families from
the same region identified the same mutation and another
mutation which causes a serine to isoleucine amino change
at codon 242 (pS242I). The mechanisms by which these mu-
tations in ZNF687 affect bone metabolism to cause PDB and
GCT remain unclear. Expression of ZNF687 increases during
osteoclastogenesis following M-CSF and RANKL treatment
of human monocytes. The gene is also expressed in mono-
cytes, osteoclasts, and osteoblasts in zebrafish, and high levels
of ZNF687 mRNA have also been found in GCT. While bio-
informatic analysis has predicted that the pP937R mutation
may enhance nuclear import of ZNF687, the consequences
of this are unclear.
Pharmacogenetics and PDB
The importance of genetic factors in PDB raises the possibility
that genetic profiling might be of value clinically in identify-
ing those at risk of the disease and also in providing markers
of response to treatment. Both of these issues are discussed in
the present section.
Genetic Markers for Susceptibility to PDB
The importance of genetic factors in PDB coupled with the
observation that risk variants have a large effect size raises the
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possibility that genetic testing could be of value in identifying
patients at risk of developing PDB or those at risk of compli-
cations [91]. This is particularly relevant in the rare syndromic
forms of PDB where the disease is inherited in a Mendelian
manner where genetic testing is already performed in children
of affected individuals. The potential role of genetic testing
coupled to therapeutic intervention is currently being explored
in the context of the ZiPP trial (ISRCTN 11616770). In this
study, adults who had a family history of PDB were offered
genetic testing for SQSTM1 mutations, and those that tested
positive were invited to take part in a randomised controlled
trial of zoledronic acid or placebo with the aim of determining
whether treatment was effective at preventing the development
of PDB [92]. Analysis of baseline characteristics showed that
about 9% of SQSTM1 mutation carriers had signs of PDB on
bone scan but were asymptomatic, and interestingly, most peo-
ple with lesions had normal levels of biochemical markers of
bone remodelling [93•]. The study remains in progress but is
due to report during 2021. Another approach used by Guay-
Belanger and colleagues combined both a genetic screening test
for SQSTM1 mutations, with a test for biochemical markers
associated with PDB [94]. This approach correctly identified
93.9% of PDB-affected patients as compared with controls.
Similarly, Albagha and colleagues evaluated the performance
of seven SNPs associated with PDB derived from GWAS with
mutations in SQSTM1 to try and predict extent and severity of
PDB in amultinational cohort of 1940 patients with the disease.
The approach was successful in identifying disease extent,
complications, and number of courses of bisphosphonates ad-
ministered [91]. Both Guay-Belanger’s study and Albagha’s
study focused on patients known to have PDB rather than those
at risk because of positive family history, and a future aim will
be to further explore the risk of genetic and other markers in
predicting risk of developing the disease.
Genetic Markers of Treatment Response
Several investigators have explored the possible role of genetic
profiling in assessing treatment response [95–97].
Bisphosphonates are generally considered to be the treatment
of first choice for PDB, and modern bisphosphonates can induce
biochemical remission in the majority of PDB patients [98, 99].
Some investigators have studied so-called acquired resistance to
bisphosphonate therapy in PDB, although these studies typically
involved patients treated with older bisphosphonates [95,
100–102]. Mossetti and colleagues [96] studied the relation be-
tween theTaqI,BsmI, andFok1 polymorphisms in theVDR gene
and response to clodronate in 84 patients with PDB as well as
possible associations between SQSTM1mutations and treatment
response in the same population. They reported a significant
association between the TaqI and BsmI polymorphisms and re-
sistance to 1500mg clodronate given intravenously by logistic
regression analysis taking other predictors into account.
Resistance was defined as lack of suppression of ALP level by
more than 50% comparedwith the starting value. The duration of
responsewas also related toVDR alleles. Therewas no difference
however in the proportion of patients with SQSTM1mutations in
the groups of patients with resistance or no resistance to
clodronate. Corral-Gudino and colleagues [95] studied the rela-
tion between polymorphisms in the IL1B, ILR1, and IL1RN
genes and response to treatment with various bisphosphonates
including etidronate, tiludronate, clodronate, risedronate and
pamidronate in 123 patients with PDB. The IL1B gene encodes
interleukin-1 beta a cytokine with stimulatory effects on osteo-
clasts; the ILR1 gene encodes the interleukin 1 receptor, and the
IL1RN gene encodes the interleukin-1 receptor antagonist. They
reported that the −511C/T polymorphism of the IL1B gene was
significantly associated with response to all bisphosphonates
grouped together [95]. Analysis of response to individual
bisphosphonates revealed notionally significant results for
tiludronate and risedronate, but the analyses were not corrected
for multiple testing. The mechanisms of acquired resistance to
bisphosphonate therapy in PDB remain poorly understood, but
several theories are proposed. The first is that bisphosphonate
therapy may select a subgroup of osteoclasts that become resis-
tant to the apoptotic effect of the drug [103]. The second is that
continued therapy with a bisphosphonate may induce enzymes
that confer resistance to a subset of osteoclasts or their precursors
[103]. It has also been proposed that acquired resistance is caused
by disease-related factors and patients with extensive PDB are
more likely to develop resistance. These studies, while of interest,
were both based on small sample size, and the results will be
required to be replicated in other populations. More recently
Visconti looked at the relation between SQSTM1 mutations
and treatment response in the PRISM study [97]. While carriers
of SQSTM1 mutations were found to have more severe disease,
there was no difference between those with and without
SQSTM1 mutations and response to treatment.
Conclusion
Genetic factors play a key role in the pathogenesis of Paget’s
disease, and huge advances have been made over the past 20
years in identifying the genetic variants that predispose to the
disease and the mechanisms by which they affect bone me-
tabolism. Further research needs to be conducted to identify ad-
ditional genes that cause the disease however, and it is likely that
extended GWAS studies, genome sequencing studies, and candi-
date gene studies may cast further light into disease mechanisms
in the future. An important direction will be to further explore the
mechanisms by which genetic variants and environmental factors
interact to influence susceptibility and disease severity, since this
is an area that is poorly understood.Advances in genetics offer the
prospect of developing a more comprehensive understanding of
the pathophysiology of PDB and open the possibility of using
Curr Osteoporos Rep
genetic testing coupled to targeted therapeutic intervention to pre-
vent disease progression and improve outcome before irreversible
skeletal damage has occurred.
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